scPharmaceuticals Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Great. Welcome back, everyone, to the next session. And apologies, we had a couple of technical issues, but we are back. So I'm Roanna Ruiz, senior biotech analyst here at SVB Securities, and it's my pleasure to introduce the management team of scPharmaceuticals. We have John Tucker, CEO; and we also have John Mohr, SVP of Clinical Development.
So welcome both of you, and I will pass it to John for a presentation of the company.
Great, Roanna. Thank you so much, and welcome, everyone. Typical forward-looking statements.
So today, I'll be quick. A quick overview on the company and then a disease overview and talk about FUROSCIX, where we're on the verge of launching and incredibly excited. And I'd spend a little bit of time on the commercial opportunity.
So company highlights. ScPharmaceuticals, the name really says what we do. We take drugs that are already in the hospital being delivered IV, and create new formulations, new delivery
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |